



National Library of Medicine

PubMed

PubMed	Nucleotide	Protein	Genome	Structure	PopSet
Search PubMed	<input checked="" type="checkbox"/> for			<input type="button" value="Go"/>	<input type="button" value="Clear"/>
		<input type="button" value="Limits"/>	<input type="button" value="Preview/Index"/>	<input type="button" value="History"/>	<input type="button" value="Clipboard"/>

Entrez PubMed

<input type="checkbox"/> 1 : <i>Arch Toxicol Suppl</i> 1996;18:333-41	<input type="button" value="Related Articles, Books"/>
---	--

PubMed Services

Unanticipated human toxicology of recombinant proteins.

Ryffel B

Institute of Toxicology, University Zurich.

Related Resources

Recombinant human proteins play already an important role in therapy, e.g. erythropoietin and colony stimulating factors, while several promising candidates such IL-6, IL-12, thrombopoietin and others are in clinical development. Since the recombinant proteins are copies of endogenous proteins, it was assumed that they would be well tolerated. While this assumption is correct for some, other proteins proved to be a highly toxic. Therefore, preclinical safety assessment of these proteins is necessary. Based on the experience with several proteins, some guidance for the safety assessment can be given. Furthermore, data are presented demonstrating that preclinical toxicity studies have a predictive value for man. Limitations of the classical approach of safety tests and new concepts are discussed.

Publication Types:

- Review
- Review, tutorial

PMID: 8678809, UI: 96242508

<input type="checkbox"/> Display	<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/> Save	<input type="checkbox"/> Text	<input type="checkbox"/> Order	<input type="checkbox"/> Add to Clipboard
----------------------------------	--	-------------------------------	-------------------------------	--------------------------------	---

Revised: April 3, 2000.

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)